Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PD-1 Progress May Shorten The Life Of Other Drugs

Executive Summary

With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?

Advertisement

Related Content

Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points
Genentech Catching Up In Melanoma With Cotellic Approval
Bristol’s Opdivo Delay May Help It Beat Out BRAF Inhibitors
Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs
Bristol-Backed Program May Spur Immunotherapy Use In Community Setting
AstraZeneca’s Oncology Strategy: It’s All About The End Results
AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
Front-Line Of Melanoma Market Could Be Marketing Battle

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel